论文部分内容阅读
目的:观察IZL-2003免疫治疗系统对恶性肿瘤放、化疗患者骨髓抑制的近期疗效和生存质量的影响。方法:将120例骨髓不同程度抑制的放、化疗患者随机分为治疗组(IZL-2003免疫治疗系统辐照)、对照组(仅常规给予维生素C、维生素B6)各60例,治疗10 d为1个疗程。结果:治疗组外周血白细胞数明显增多,与对照组比较,差异有显著性(P<0.05);治疗组与对照组KPS改善率分别为28.33%和10.00%,恶化率分别为31.67%和53.33%,两组比较,差异有显著性(P<0.05)。生存质量治疗组优于对照组(P<0.05)。结论:IZL-2003免疫治疗系统辐照能拮抗放、化疗所致白细胞减少,并在一定程度上改善患者KPS评分,提高生存质量。
Objective: To observe the effect of IZL-2003 immunotherapy system on the short-term efficacy and quality of life of myelosuppression in patients with radiotherapy and chemotherapy of malignant tumor. Methods: 120 cases of radiotherapy and chemotherapy with different degree of bone marrow suppression were randomly divided into treatment group (irradiation with IZL-2003 immunotherapy system) and control group (with routine administration of vitamin C and vitamin B6), 60 cases each for 10 days 1 course of treatment. Results: Compared with the control group, the number of peripheral blood leukocytes in treatment group increased significantly (P <0.05). The improvement rates of KPS in treatment group and control group were 28.33% and 10.00% respectively, and the rates of deterioration were 31.67% and 53.33 %, The difference between the two groups was significant (P <0.05). The quality of life treatment group was better than the control group (P <0.05). Conclusion: IZL-2003 immunotherapy system can antagonize radiotherapy and chemotherapy induced leukopenia, and to some extent, improve KPS score and improve quality of life.